Literature DB >> 10875087

Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity.

T L Young1, D C Anthony, E Pierce, E Foley, L E Smith.   

Abstract

OBJECTIVES: We had the unique opportunity to compare the eyes of a premature infant with stage 3 retinopathy of prematurity (ROP) in both eyes after the condition was treated by diode laser photocoagulation in one eye only. After the infant's death, we investigated the extent of structural damage incurred with the diode laser and examined the effect of treatment on vascular endothelial growth factor (VEGF) expression.
METHODS: The eyes were fixed and embedded in paraffin. Adjacent 6 microns sections were either stained for histopathologic analysis or used for in situ hybridization. VEGF messenger RNA (mRNA) was detected by using radiolabeled antisense riboprobes.
RESULTS: In the treated eye, histopathologic results demonstrated the clinically evident dose-response effect, with sparing of inner retinal elements with mild laser burns and full-thickness retinal cell disruption with severe burns. Scleral and ciliary nerve effects were absent. VEGF mRNA was localized primarily in the ganglion cell layer but was also found in the inner nuclear layer. In the untreated eye, an increase in VEGF mRNA was detected at the peripheral edge of the vascularized retina anterior to the ridge. In the laser-treated eye, VEGF mRNA expression was dramatically upregulated in the ganglion cell layer in areas adjacent to laser burns.
CONCLUSIONS: VEGF mRNA was found to be elevated in the peripheral, avascular retina of the untreated eye, consistent with the hypothesis that retinal hypoxia stimulates VEGF expression. In the treated eye with recurrent ROP, VEGF mRNA was not detected in the photocoagulated areas of retina but was increased between laser scars. This finding confirms the results of prior animal studies and validates the use of these models.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10875087     DOI: 10.1016/s1091-8531(97)90008-2

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  31 in total

1.  Retinal neovascular markers in retinopathy of prematurity: aetiological implications.

Authors:  P E North; D C Anthony; T L Young; M Waner; H H Brown; M C Brodsky
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

Review 2.  The management of retinopathy of prematurity.

Authors:  J D Reynolds
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

Review 4.  Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies.

Authors:  Gerd Holmström; Peter van Wijngaarden; Douglas J Coster; Keryn A Williams
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

5.  [Pharmacological treatment for retinopathy of prematurity].

Authors:  A Stahl; H Agostini; C Jandeck; W Lagrèze
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

6.  Intravitreal injection of bevacizumab for retinopathy of prematurity.

Authors:  Kazuki Kuniyoshi; Koji Sugioka; Hiroyuki Sakuramoto; Shunji Kusaka; Norihisa Wada; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2014-02-26       Impact factor: 2.447

7.  Dynamics of human foveal development after premature birth.

Authors:  Ramiro S Maldonado; Rachelle V O'Connell; Neeru Sarin; Sharon F Freedman; David K Wallace; C Michael Cotten; Katrina P Winter; Sandra Stinnett; Stephanie J Chiu; Joseph A Izatt; Sina Farsiu; Cynthia A Toth
Journal:  Ophthalmology       Date:  2011-09-21       Impact factor: 12.079

8.  Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.

Authors:  David Morrison; James Shaffer; Gui-Shuang Ying; Gil Binenbaum
Journal:  J AAPOS       Date:  2018-03-14       Impact factor: 1.220

9.  The use of digital imaging in the identification of skip areas after laser treatment for retinopathy of prematurity and its implications for education and patient care.

Authors:  Kai B Kang; Anton Orlin; Thomas C Lee; Michael F Chiang; R V Paul Chan
Journal:  Retina       Date:  2013 Nov-Dec       Impact factor: 4.256

Review 10.  The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment.

Authors:  Lois E Smith; Anna-Lena Hard; Ann Hellström
Journal:  Clin Perinatol       Date:  2013-06       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.